Millipore Sigma Vibrant Logo

324630 EHNA, Hydrochloride - CAS 51350-19-7 - Calbiochem

The racemic mixture of a cell-permeable adenine derivative that acts as a PDE II-selective phosphodiesterase inhibitor and adenosine deaminase.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: erythro-9-(2-Hydroxy-3-nonyl)adenine, HCl

Primary Target: PDE 2
324630
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

Empirical FormulaCAS #
C₁₄H₂₃N₅O · HCl51350-19-7

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
324630-10MGCN
Retrieving availability...
—
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewThe racemic mixture of a cell-permeable adenine derivative that acts as a PDE II-selective phosphodiesterase inhibitor (IC50 = 0.8 and 2 µM against human and procine PDE II, respectively) and adenosine deaminase (Ki = 4 nM), while exhibiting little or much reduced potency toward PDE I/II/IV isozymes (IC50 >100 µM) of both human and porcine species. EHNA at 10 µM concentration is also reported to effectively and reversibly block the differentiation and maintain the pluripotency of hES (human embryonic stem) cell line SA121 in feeder-free cultures without exogenously added FGF for up to 30 passages in a manner independent of its known ADA and PDE inhibitory activities.
      Catalogue Number324630
      Brand Family Calbiochem®
      Synonymserythro-9-(2-Hydroxy-3-nonyl)adenine, HCl
      References
      ReferencesBurton, P., et al. 2010. Biochem. J. in press.
      Lorbar, M., et al. 1999. J. Mol. Cell. Cardiol. 31, 401.
      Verde, I., et al. 1999. Br. J. Pharmacol. 127, 65.
      Reynolds, A.J., et al. 1996. Brain Res. 798, 67.
      Mery, P.F., et al. 1995. Mol. Pharmacol. 48, 121.
      Podzuweit, T., et al. 1995. Cell. Signal. 7, 733.
      Bessodes, M., et al. 1982. Biochem. Pharmacol. 31, 879.
      Bouchard, P., et al. 1981. Proc. Natl. Acad. Sci. USA 78, 1033.
      Product Information
      CAS number51350-19-7
      ATP CompetitiveN
      FormWhite solid
      Hill FormulaC₁₄H₂₃N₅O · HCl
      Chemical formulaC₁₄H₂₃N₅O · HCl
      Hygroscopic Hygroscopic
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetPDE 2
      Primary Target IC<sub>50</sub>0.8 and 2 µM against human and procine PDE II, respectively
      Primary Target K<sub>i</sub>4 nM against adenosine deaminase
      Purity≥97% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      EHNA, Hydrochloride - CAS 51350-19-7 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      EHNA, Hydrochloride - CAS 51350-19-7 - Calbiochem Certificates of Analysis

      TitleLot Number
      324630

      References

      Reference overview
      Burton, P., et al. 2010. Biochem. J. in press.
      Lorbar, M., et al. 1999. J. Mol. Cell. Cardiol. 31, 401.
      Verde, I., et al. 1999. Br. J. Pharmacol. 127, 65.
      Reynolds, A.J., et al. 1996. Brain Res. 798, 67.
      Mery, P.F., et al. 1995. Mol. Pharmacol. 48, 121.
      Podzuweit, T., et al. 1995. Cell. Signal. 7, 733.
      Bessodes, M., et al. 1982. Biochem. Pharmacol. 31, 879.
      Bouchard, P., et al. 1981. Proc. Natl. Acad. Sci. USA 78, 1033.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision09-February-2012 RFH
      Synonymserythro-9-(2-Hydroxy-3-nonyl)adenine, HCl
      DescriptionThe racemic mixture of a cell-permeable adenine derivative that acts as a PDE II-selective phosphodiesterase inhibitor (IC50 = 0.8 and 2 µM against human and procine PDE II, respectively) and adenosine deaminase (Ki = 4 nM), while exhibiting little or much reduced potency toward PDE I/II/IV isozymes (IC50 >100 µM) of both human and porcine species. EHNA at 10 µM concentration is also reported to effectively and reversibly block the differentiation and maintain the pluripotency of hES (human embryonic stem) cell line SA121 in feeder-free cultures without exogenously added FGF for up to 30 passages in a manner independent of its known ADA and PDE inhibitory activities.
      FormWhite solid
      CAS number51350-19-7
      Chemical formulaC₁₄H₂₃N₅O · HCl
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityH₂O (25 mg/ml)
      Storage +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesBurton, P., et al. 2010. Biochem. J. in press.
      Lorbar, M., et al. 1999. J. Mol. Cell. Cardiol. 31, 401.
      Verde, I., et al. 1999. Br. J. Pharmacol. 127, 65.
      Reynolds, A.J., et al. 1996. Brain Res. 798, 67.
      Mery, P.F., et al. 1995. Mol. Pharmacol. 48, 121.
      Podzuweit, T., et al. 1995. Cell. Signal. 7, 733.
      Bessodes, M., et al. 1982. Biochem. Pharmacol. 31, 879.
      Bouchard, P., et al. 1981. Proc. Natl. Acad. Sci. USA 78, 1033.